CA-VEEVA-SYSTEMS
4.2.2021 13:05:06 CET | Business Wire | Press release
Veeva Systems (NYSE: VEEV) today announced that 6 out of the top 7 global CROs have joined the Veeva Vault CDMS partner program. Accelerating clinical research is a top priority in the life sciences industry. All of the top 7 CROs, except IQVIA, which has decided not to join the program at this time, are now able to leverage Veeva Vault CDMS capabilities to modernize clinical data management and build high-quality studies faster.
The growth of Veeva’s CRO partner program is enabling an industrywide shift to a modern clinical data management platform that better meets the needs of today’s clinical trials. Now 6 out of the top 7 global CROs have access to the support and training needed to build and execute studies with Veeva. As the need to run faster and more efficient trials grows, CROs are using Veeva's advanced technology to help sponsors improve trial performance.
“Veeva is enabling CROs to work more effectively with sponsors during the build process to accelerate trial starts,” said Henry Levy, general manager of Veeva Vault CDMS. “Our CRO partners are leading the way towards faster, more collaborative studies and continued excellence in trials.”
Vault CDMS is a modern cloud application suite that combines electronic data capture (EDC) , coding , data cleaning , and reporting . Customers are able to build study databases in six weeks or less and make mid-study amendments with zero downtime, freeing customers to run the trials they want without technology limitations.
Emerging biotechs are benefitting from the growing number of CROs adopting Vault CDMS. The access to a modern clinical data management solution provides them with the speed and nimbleness to accelerate clinical research.
The six global CROs joining Veeva’s partner program are Covance, ICON, Parexel, PPD, PRA Health Sciences, and Syneos Health. For CROs interested in learning more about the program, contact info@veeva.com .
What CROs are saying about Veeva Vault CDMS:
“ICON supports clients to accelerate clinical development and advance healthcare through applied technology,” said Lalit Pai, senior vice president, biometrics at ICON . “Veeva’s innovative clinical data management platform is enabling us to manage and deliver seamless integration for our clients and meet rigorous, global quality standards.”
“Veeva has an outstanding reputation in the industry and within our organization, as we have widely adopted many of its other platforms,” said Simon Fleming, vice president, data management at Parexel . “Veeva Vault CDMS provides us with an exciting opportunity to further build on our relationship and provide customers with more choice and flexibility.”
“PPD continues to expand our technology offerings focused on providing accelerated decision-making for our customers,” said Rob Petrie, senior vice president and chief technology officer at PPD . “The implementation of Veeva Vault CDMS provides PPD the flexibility to continue to provide innovative technologies, furthering PPD’s mission of bending the time and cost curve of drug development and enabling our clinical research teams to continue to raise the bar by providing the highest level of service and quality to our customers.”
“Veeva Vault CDMS is a valuable addition to our existing biometrics technology offerings and will provide our clients and partners with a greater choice,” said Michael Goedde, vice president, global data operations at PRA Health Sciences . “Veeva has been a respected and valued partner of ours for many years, and now we will be able to further enhance our clinical data management services as the drug development industry evolves.”
“At Syneos Health, our focus has always been on running clinical trials in the most efficient and integrated manner, and with the highest quality processes and procedures,” said Paul Colvin, president, clinical solutions at Syneos Health . “Our long-standing relationship with Veeva, combined with Veeva Vault CDMS, will allow us to accelerate our operational capabilities and work more collaboratively with our clients.”
Additional Information
For more on Veeva Vault CDMS, visit: veeva.com/CDMS
Connect with Veeva on LinkedIn: linkedin.com/company/veeva-systems
Follow @veeva_eu on Twitter: twitter.com/veeva_eu
Like Veeva on Facebook: facebook.com/veevasystems
About Veeva Systems
Veeva Systems Inc. is the leader in cloud-based software for the global life sciences industry. Committed to innovation, product excellence, and customer success, Veeva serves more than 950 customers, ranging from the world’s largest pharmaceutical companies to emerging biotechs. Veeva is headquartered in the San Francisco Bay Area, with offices throughout North America, Europe, Asia, and Latin America. For more information, visit veeva.com/eu .
Forward-looking Statements
This release contains forward-looking statements, including the market demand for and acceptance of Veeva’s products and services, the results from use of Veeva’s products and services, and general business conditions (including the on-going impact of COVID-19), particularly within the life sciences industry. Any forward-looking statements contained in this press release are based upon Veeva’s historical performance and its current plans, estimates, and expectations, and are not a representation that such plans, estimates, or expectations will be achieved. These forward-looking statements represent Veeva’s expectations as of the date of this press announcement. Subsequent events may cause these expectations to change, and Veeva disclaims any obligation to update the forward-looking statements in the future. These forward-looking statements are subject to known and unknown risks and uncertainties that may cause actual results to differ materially. Additional risks and uncertainties that could affect Veeva’s financial results are included under the captions, “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations,” in the company’s filing on Form 10-Q for the period ended October 31, 2020. This is available on the company’s website at veeva.com under the Investors section and on the SEC’s website at sec.gov . Further information on potential risks that could affect actual results will be included in other filings Veeva makes with the SEC from time to time.
® 2021 Veeva Systems Inc. All rights reserved. Veeva and the Veeva logo are trademarks of Veeva Systems Inc.
Veeva Systems Inc. owns other registered and unregistered trademarks.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210204005394/en/
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
NetJets Becomes Official Private Aviation Provider of the Hahnenkamm Races in Kitzbühel20.11.2026 18:45:00 CET | Press release
The Partnership brings together two brands committed to excellence, precision and exceptional experiences NetJets, the global leader in private aviation, is delighted to announce its newest partnership with the Hahnenkamm Races in Kitzbühel, Austria, becoming the event's Official Private Aviation Provider. The Hahnenkamm Races are among the most prestigious and celebrated events in world alpine skiing. They attract athletes, business leaders, international guests and winter sports enthusiasts from around the world. Through this partnership, NetJets and the Hahnenkamm Races are aligning two brands renowned for excellence, precision and world-class experiences. The partnership is an exciting addition to NetJets' growing portfolio of premium lifestyle and sporting partnerships, offering Owners unique opportunities to access one of Europe's most iconic winter sporting events. Alongside premium hospitality and unforgettable behind-the-scenes experiences, the collaboration will help create e
Frontgrade Technologies Help Power Critical Computing and Electronics Aboard NASA’s Roman Space Telescope20.11.2026 18:40:00 CET | Press release
Frontgrade processors and radiation-hardened microelectronics support critical spacecraft and instrument functions on NASA’s flagship astrophysics mission Frontgrade today announced that technologies from across its space electronics portfolio are supporting multiple mission-critical systems aboard NASA’s Nancy Grace Roman Space Telescope, which successfully launched on August 30, 2026. Roman is NASA’s flagship astrophysics observatory designed to investigate dark energy, discover exoplanets and explore the evolution of the universe. Its onboard electronics include radiation-hardened processors and microelectronics, providing critical processing, communications, power-management and control functions across the spacecraft. At the centre of Roman’s computing architecture are Frontgrade Gaisler’s GR740 and GR712RC processors. The GR740 radiation-hardened quad-core LEON4FT processor serves as the computing engine for the Wildcat Processor Card, used in the spacecraft’s primary and redunda
Inside Moutai House Singapore: Beyond Baijiu, A Cultural Encounter20.11.2026 16:05:00 CET | Press release
On November 13, Moutai House officially opened at Fullerton Waterboat House in Singapore. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261120301288/en/ On November 13, Moutai House officially opened at Fullerton Waterboat House in Singapore. As the world’s first Moutai brand experience space built under its new SI standards, this three-storey venue brings together cultural exhibitions, baijiu tasting, distinctive dining and creative cocktails. Using Moutai as a bridge, it creates new opportunities for Chinese baijiu culture to blend with and draw inspiration from Singapore’s diverse lifestyle and cultural scene. As early as 1954, Guizhou Moutai arrived in Singapore via the Singapore River, marking its first entry into Southeast Asia, right across from Fullerton Waterboat House. 72 years later, Moutai House has found its home along the same riverbank, transforming a historic arrival into a lasting presence and turning a con
ViTAA Medical and The Society for Vascular Surgery Announce Strategic Partnership20.11.2026 15:00:00 CET | Press release
ViTAA Medical to Become Key SVS AI Partner, Advancing AI Education and Responsible Adoption in Vascular Care ViTAA Medical Solutions Inc. (ViTAA) today announced a strategic partnership with The Society for Vascular Surgery (SVS) to advance evidence, education, and the responsible adoption of quantitative imaging and artificial intelligence in vascular care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261120954362/en/ The partnership will support evidence building, best practices, educational resources for SVS members, physicians and trainees on AI validation, interpretation, and clinical limitations. The relationship has the potential to pave the way for additional AI tools and resources for SVS members through the Society in the future. The partnership creates a framework for the organizations to lead AI-enabled research opportunities involving imaging and clinical outcomes. Mitchel Benovoy, PhD, Chief Executive Officer
Epitech Group and Horus Pharma sign a global licensing agreement to develop adelmidrol in eye health20.11.2026 14:39:00 CET | Press release
Epitech Group S.p.A., an Italian biopharmaceutical firm specializing in neuro-inflammation, and Horus Pharma, a French laboratory specializing in ophthalmology, announce a global licensing agreement for adelmidrol, a molecule belonging to the ALIAmide family, developed by Epitech Group. This agreement grants Horus Pharma exclusive rights to develop and market adelmidrol for human ophthalmology and periocular dermatology applications. It aims to explore new approaches to address unmet medical needs in eye health. A combination of complementary scientific expertise Epitech Group has been studying ALIAmides and their role in physiological regulatory mechanisms for over 30 years, building on the research of Rita Levi-Montalcini, the 1986 Nobel Prize in Medicine laureate who first identified the ALIA mechanism. Horus Pharma, for its part, contributes over 20 years of ophthalmology expertise, strong R&D capabilities, and its international presence. Against the backdrop of an aging population
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
